About Cingulate
Cingulate is a company based in Kansas City (United States) founded in 2012 by Craig S Gilgallon and Shane J Schaffer. It operates as a Professional Services. Cingulate has raised $33 million across 6 funding rounds from investors including The Werth Family Foundation, Salem Investment Partners and Lincoln Park Capital. The company has 13 employees as of December 31, 2024. Cingulate offers products and services including CTx-1301, CTx-1302, and CTx-2103. Cingulate operates in a competitive market with competitors including Lyndra, Nura Bio, Healx, i2o Therapeutics and Cure Pharmaceutical, among others.
- Headquarter Kansas City, United States
- Employees 13 as on 31 Dec, 2024
- Founders Craig S Gilgallon, Shane J Schaffer
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cingulate Inc.
-
Annual Revenue
Not available
-
Net Profit
-$15.55 M (USD)33.95as on Dec 31, 2024
-
EBITDA
-$14.99 M (USD)32.4as on Dec 31, 2024
-
Total Equity Funding
$33 M (USD)
in 6 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jul 22, 2025
-
Investors
The Werth Family Foundation
& 2 more
-
Employee Count
13
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cingulate
Cingulate is a publicly listed company on the NASDAQ with ticker symbol CING in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cingulate
Cingulate offers a comprehensive portfolio of products and services, including CTx-1301, CTx-1302, and CTx-2103.
A medication developed for treating ADHD with precision dosing.
Another formulation created for ADHD treatment with controlled release.
A candidate developed for managing anxiety-related disorders effectively.
Funding Insights of Cingulate
Cingulate has successfully raised a total of $33M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cingulate
Cingulate has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include The Werth Family Foundation, Salem Investment Partners and Lincoln Park Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward North American opportunities.
|
Locked | Locked | Locked | |
|
Nonprofit organization offering community aid, global assistance, and data-driven solutions.
|
Locked | Locked | Locked |
Investor details for Cingulate
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cingulate
Investment portfolio details for Cingulate
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cingulate
Detailed financials for Cingulate
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cingulate Comparisons
Peer comparison for Cingulate
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cingulate
Cingulate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lyndra, Nura Bio, Healx, i2o Therapeutics and Cure Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovates long-acting oral therapies to simplify patient medication regimens.
|
|
| Locked | Locked | Locked |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for rare diseases is developed.
|
|
| Locked | Locked | Locked |
Oral drug delivery solutions are provided via liquid technology platform.
|
|
| Locked | Locked | Locked |
Oral thin film-based drug delivery systems are developed.
|
|
| Locked | Locked | Locked |
Proprietary platform is utilized for extended-release CNS drug development.
|
Detailed competitors of Cingulate
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cingulate
Complete news archive for Cingulate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cingulate
Cingulate was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Cingulate is headquartered in Kansas City, United States. It is registered at Kansas City, Missouri, United States.
Shane J Schaffer is the current CEO of Cingulate. They have also founded this company.
Cingulate is a funded company, having raised a total of $33M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Cingulate is 13.
Cingulate Inc. is a clinical-stage biopharmaceutical company engaged in the development of innovative treatments for central nervous system disorders, particularly Attention DeficitHyperactivity Disorder (ADHD) and anxiety-related conditions. Two product candidates, CTx-1301 and CTx-1302, are being developed for the ADHD market, valued at approximately 18 billion annually in the US. Additionally, CTx-2103 is under development for the 5 billion US anxiety market. Proprietary technology, such as the Precision Timed Release Platform, is utilized to ensure precise once-daily dosing. The company operates within the healthcare and biotechnology sector, focusing on neurobiological solutions.
Cingulate's top competitors include Healx, Nura Bio and i2o Therapeutics.
Cingulate offers CTx-1301, CTx-1302, and CTx-2103.
Yes, Cingulate is publicly traded on NASDAQ under the ticker symbol CING.
Cingulate has 3 investors. Key investors include The Werth Family Foundation, Salem Investment Partners, and Lincoln Park Capital.
The ticker symbol of Cingulate is CING on NASDAQ.